|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
2,250,000,000 |
Market
Cap: |
99.47(B) |
Last
Volume: |
13,246,446 |
Avg
Vol: |
11,944,728 |
52
Week Range: |
$44.7 - $69.08 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 100 |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 11.3 |
Insider 3/6 Months : 11.9 |
|
Guru Rank Number : 97 |
Guru Rank Value : 8.6 |
Guru Occurances : 3 |
|
|
|
|
|
|
|
Company Profile Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
13,571 |
13,571 |
13,571 |
Total Buy Value |
$0 |
$672,994 |
$672,994 |
$672,994 |
Total People Bought |
0 |
2 |
2 |
2 |
Total Buy Transactions |
0 |
3 |
3 |
3 |
Total Shares Sold |
0 |
0 |
69,103 |
681,397 |
Total Sell Value |
$0 |
$0 |
$4,525,215 |
$49,727,684 |
Total People Sold |
0 |
0 |
3 |
6 |
Total Sell Transactions |
0 |
0 |
3 |
12 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Elkins David V |
EVP, Chief Financial Officer |
|
2021-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,792 |
88,800 |
|
- |
|
Boerner Christopher S. |
EVP, Chief Commercial Officer |
|
2021-12-02 |
4 |
D |
$55.41 |
$74,804 |
D/D |
(1,350) |
38,512 |
|
- |
|
Boerner Christopher S. |
EVP, Chief Commercial Officer |
|
2021-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,638 |
39,862 |
|
- |
|
Vessey Rupert |
EVP, Research & Early Dev. |
|
2021-12-02 |
4 |
D |
$55.41 |
$249,234 |
D/D |
(4,498) |
51,258 |
|
- |
|
Vessey Rupert |
EVP, Research & Early Dev. |
|
2021-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,792 |
55,756 |
|
- |
|
Von Autenried Paul |
EVP, Chief Information Officer |
|
2021-11-24 |
4 |
S |
$56.92 |
$987,733 |
I/I |
(17,353) |
63,536 |
|
-36% |
|
Von Autenried Paul |
EVP, Chief Information Officer |
|
2021-11-23 |
4 |
S |
$57.47 |
$886,072 |
I/I |
(15,418) |
80,889 |
|
-31% |
|
Von Autenried Paul |
EVP, Chief Information Officer |
|
2021-11-22 |
4 |
S |
$57.17 |
$1,049,813 |
I/I |
(18,363) |
96,307 |
|
-30% |
|
Caforio Giovanni |
Board Chair and CEO |
|
2021-09-20 |
4 |
AS |
$60.64 |
$1,516,000 |
D/D |
(25,000) |
483,980 |
|
7% |
|
Elkins David V |
EVP, Chief Financial Officer |
|
2021-08-12 |
4 |
S |
$66.88 |
$6,674,497 |
D/D |
(99,691) |
80,008 |
|
7% |
|
Elkins David V |
EVP, Chief Financial Officer |
|
2021-08-12 |
4 |
OE |
$48.49 |
$3,394,300 |
D/D |
70,000 |
139,699 |
|
- |
|
Judge Ann Powell |
EVP, Chief Human Resources |
|
2021-08-03 |
4 |
S |
$68.57 |
$1,596,310 |
D/D |
(23,280) |
47,613 |
|
19% |
|
Caforio Giovanni |
Chairman and CEO |
|
2021-08-02 |
4 |
S |
$68.58 |
$1,371,600 |
D/D |
(20,000) |
508,980 |
|
15% |
|
Elkins David V |
EVP, Chief Financial Officer |
|
2021-08-01 |
4 |
D |
$67.87 |
$1,610,962 |
D/D |
(23,736) |
109,699 |
|
- |
|
Elkins David V |
EVP, Chief Financial Officer |
|
2021-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
46,403 |
133,435 |
|
- |
|
Leung Sandra |
EVP, General Counsel |
|
2021-07-30 |
4 |
S |
$68.04 |
$1,999,696 |
D/D |
(29,390) |
339,967 |
|
15% |
|
Von Autenried Paul |
EVP, Chief Information Officer |
|
2021-07-30 |
4 |
GA |
$0.00 |
$0 |
I/I |
114,670 |
114,670 |
|
- |
|
Von Autenried Paul |
EVP, Chief Information Officer |
|
2021-07-30 |
4 |
GD |
$0.00 |
$0 |
D/D |
114,670 |
0 |
|
- |
|
Von Autenried Paul |
EVP, Chief Information Officer |
|
2021-07-30 |
4 |
S |
$68.06 |
$1,701,375 |
D/D |
(25,000) |
114,670 |
|
15% |
|
Vessey Rupert |
EVP, Research & Early Dev. |
|
2021-07-30 |
4 |
S |
$68.01 |
$10,782,154 |
D/D |
(158,393) |
46,964 |
|
15% |
|
Vessey Rupert |
EVP, Research & Early Dev. |
|
2021-07-30 |
4 |
OE |
$44.70 |
$8,830,108 |
D/D |
150,967 |
187,617 |
|
- |
|
Dubow Adam |
SVP,ChiefCompliance&EthicsOff. |
|
2021-07-30 |
4 |
S |
$67.90 |
$167,441 |
D/D |
(2,466) |
13,777 |
|
15% |
|
Santiago Karen Murphy |
SVP & Controller |
|
2021-07-01 |
4 |
D |
$66.56 |
$36,408 |
D/D |
(547) |
14,498 |
|
- |
|
Santiago Karen Murphy |
SVP & Controller |
|
2021-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,069 |
15,045 |
|
- |
|
Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
|
2021-07-01 |
4 |
D |
$66.56 |
$318,556 |
D/D |
(4,786) |
11,752 |
|
- |
|
2225 Records found
|
|
Page 8 of 89 |
|
|